1-4 of 4
Yajin Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Available to Purchase
Ningning Zhang, Tian Liu, Ming Luo, Jihui Hao, Shukui Qin, Yanqiao Zhang, Gang Wang, Yajin Chen, Jingdong Zhang, Shanzhi Gu, Junqi Niu, Guijie Xin, Ge Yu, Yabing Guo, Chongyuan Xu, Jun Yao, Jie Shen, Aibing Xu, Shuwen Zhang, Di Yang, Meijuan Gao, Ruixuan Luo, Yebo He, Fei Zheng, Nan Cao, Xiaolu Tao
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-3412
Published: 01 July 2025
View article titled, Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Open the PDF for Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study in another window
Includes: Supplementary data
Journal Articles

Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma

Available to Purchase
Hongkai Zhuang, Chenwei Tang, Wentao Wang, Bo Chen, Bingkun Wang, Yonglin Hua, Xiaowu Ma, Qingbin Wang, Wenliang Tan, Lei Yang, Zhiqin Xie, Yajin Chen, Changzhen Shang
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF16.
https://doi.org/10.1158/1078-0432.CCR-24-4338
Published: 05 June 2025
View article titled, Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
Open the PDF for Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

Available to Purchase
Yajin Chen, Chengyou Du, Shunli Shen, Wu Zhang, Yunfeng Shan, Ang Lyu, Jianhui Wu, Changzhen Shang, Xuan Luo, Jinxing Wei, Heng Xiao, Jianguo Qiu, Yunpeng Hua, Shutong Wang, Ting Wang, Shengjie Dai, Shuhao Zhang, Bingying Xie, Yinghao Wu, Chunyi Hao
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2937–2944.
https://doi.org/10.1158/1078-0432.CCR-24-0006
Published: 15 July 2024
View article titled, Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
Open the PDF for Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

Free
Qingfeng Xiang, Weiqiang Chen, Meng Ren, Jingnan Wang, Hongwu Zhang, David Y.B. Deng, Lei Zhang, Changzhen Shang, Yajin Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2959–2970.
https://doi.org/10.1158/1078-0432.CCR-13-2620
Published: 29 May 2014
View article titled, Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Open the PDF for Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET in another window
Includes: Supplementary data